Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

608
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
608
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

546
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
546
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

550
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
550
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

315
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
315
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Serotonin 5-HT7 receptor signaling modulates inflammatory responses and survival after myocardial infarction.

Journal of translational medicine·2026
Same author

Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients from the D-SOLVE and HDV-1000 consortia.

Gut·2026
Same author

Letter on 'Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors'. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Immunomodulatory effects of cannabis use: a multi-omics study in people living with HIV.

Brain, behavior, & immunity - health·2026

Related Experiment Video

Updated: Jun 15, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.8K

No value of non-selective beta-blockers after TIPS-insertion.

Anja Tiede1,2, Lena Stockhoff1, Hannah Rieland1

  • 1Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover, Germany.

Alimentary Pharmacology & Therapeutics
|August 28, 2024
PubMed
Summary
This summary is machine-generated.

Non-selective beta-blockers (NSBB) do not appear to impact systemic inflammation, hepatic decompensation, or survival after transjugular intrahepatic portosystemic shunt (TIPS) insertion. Continued NSBB therapy post-TIPS also showed no significant benefit in patient outcomes.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.0K
A Closed-chest Model to Induce Transverse Aortic Constriction in Mice
08:10

A Closed-chest Model to Induce Transverse Aortic Constriction in Mice

Published on: April 5, 2018

19.0K

Related Experiment Videos

Last Updated: Jun 15, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.8K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.0K
A Closed-chest Model to Induce Transverse Aortic Constriction in Mice
08:10

A Closed-chest Model to Induce Transverse Aortic Constriction in Mice

Published on: April 5, 2018

19.0K

Area of Science:

  • Hepatology
  • Cardiology
  • Immunology

Background:

  • Non-selective beta-blockers (NSBB) are standard for portal hypertension.
  • The role of NSBB after transjugular intrahepatic portosystemic shunt (TIPS) insertion requires clarification.
  • Potential anti-inflammatory effects of NSBB may be independent of pressure reduction.

Purpose of the Study:

  • To evaluate NSBB's impact on systemic inflammation (SI) post-TIPS.
  • To assess NSBB's association with hepatic decompensation and survival after TIPS.
  • To determine if NSBB benefits are independent of portal pressure reduction.

Main Methods:

  • Retrospective analysis of 305 patients regarding NSBB use and outcomes.
  • Prospective cohort study of 45 patients analyzing 48 soluble inflammatory markers (SIMs).
  • Multivariable competing-risk analyses for complications and mortality during 1-year follow-up.

Main Results:

  • NSBB use at TIPS insertion or continuation post-discharge did not reduce hepatic decompensation or mortality.
  • No significant association found between NSBB intake and lower levels of inflammatory markers (WBC, CRP, SIMs).
  • Peri- and post-TIPS outcomes were not significantly improved by NSBB therapy.

Conclusions:

  • NSBB therapy at TIPS insertion and its subsequent management do not significantly impact SI.
  • NSBB use does not appear to influence the development of hepatic decompensation or patient survival post-TIPS.
  • Findings suggest NSBB's role in post-TIPS care regarding inflammation and decompensation is limited.